Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.
H. Jack West, MD
From this week's
: "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors". This is largest evaluation of this topic, providing details of how , when, from what regimens, & how often fatalities from immunotherapy occur. Worth knowing.
We usually only hear and read about the bright side of #cancer immunotherapy. Here's the dark side:
Nice review in
details incidence and timing of #immunotherapy-related fatalities
$BMY $MRK $RHHBY $AZN $PFE
Toni Choueiri, MD
Great work from
pharmacovigilance data to study fatal immune-related AEs
, rare but important to be aware.
Fatal toxicity with immune checkpoint inhibitors is not common but does occur; vigilance remains key; most occur in the early period (median 40 days with single agent; 14 days with combination)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis. A broad range of regimen-specific toxic effects caused fatalities in 0.3% to 1.3% of treated patients. JAMA
Raul Cordoba, MD, PhD
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis #ImmunoOnc
Ola Landgren, M.D.
Mechanisms of fatal Immune checkpoint inhibitor (ICI) events: large study shows early onset of death with varied causes. Risk varies by therapeutic regimen. Rare events. Important clinical knowledge. #mmsm